GSK Advances Share Buyback Program with Recent Purchase

An announcement from GlaxoSmithKline ( (GB:GSK) ) is now available.

GSK has announced the purchase of 180,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas. This transaction, part of a non-discretionary agreement, contributes to the total of 7,128,500 shares bought back since September 2025. The shares will be held as treasury shares, and the company now holds a total of 254,593,344 shares in treasury, with 4,060,827,442 shares in issue. This move is likely to impact the company’s stock value and shareholder voting rights, with treasury shares accounting for 6.27% of voting rights.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £1700.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

Spark’s Take on GB:GSK Stock

According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.

GlaxoSmithKline’s strong financial performance and positive earnings call sentiment are the most significant factors driving the stock score. The company’s robust growth in specialty medicines and successful R&D efforts contribute positively. Technical analysis supports a bullish outlook, while valuation remains reasonable with an attractive dividend yield. Challenges in the U.S. vaccines market and clinical trial delays are noted but do not significantly detract from the overall positive outlook.

To see Spark’s full report on GB:GSK stock, click here.

More about GlaxoSmithKline

GlaxoSmithKline (GSK) is a major player in the pharmaceutical industry, focusing on the development and production of vaccines, medicines, and consumer healthcare products. The company is known for its commitment to innovation and improving global health outcomes.

Average Trading Volume: 8,091,343

Technical Sentiment Signal: Buy

Current Market Cap: £71.64B

For detailed information about GSK stock, go to TipRanks’ Stock Analysis page.